Portfolio

Contact:   Peter Devine

QRxPharma developed a pain therapy to NDA stage with the U.S. FDA.  In May 2007, QRx-Pharma merged with a US based biotechnology company (CNSCo Inc) and raised $50 million via an ASX listing at a pre-investment valuation of $100 million. At that time, Uniseed got back more than the funds it had invested.

Awards & recognition:

  • New Product Innovation of the Year 2010: QRxPharma Limited (ASX: QRX) was awarded the 2010 North American Frost & Sullivan Award for New Product Innovation of the Year for its lead compound MoxDuo-IR. Frost and Sullivan is a global research and market analysis firm, and this award was the culmination of their comprehensive analysis of the opioid pain management market.